Background {#Sec1}
==========

Coffee is one of the most commonly consumed beverages worldwide.^[@CR1]^ Coffee is mostly consumed as instant or ground with the type of coffee consumed varying between countries.^[@CR2]^ Instant and ground coffee have different chemical compounds, reflecting the processes involved in their production. For instance, instant coffee is reported to have higher concentrations of caffeine, polyphenols and chlorogenic acid, which contribute to antioxidant activity.^[@CR3],[@CR4]^ Instant coffee receipt has also been shown to reduce the size and number of neoplastic lesions, compared with conventional coffee or caffeine only, in an experimental study in rats.^[@CR5]^ However, instant coffee also contains twice as much acrylamide as ground coffee,^[@CR6]^ a substance which was classified in group 2A as a probable human carcinogen,^[@CR7]^ and about which there has been recent controversy regarding potential cancer risk in humans.^[@CR8],[@CR9]^

Various meta-analyses have been conducted into the association between coffee consumption and risk of digestive cancers. A recent meta-analysis by the World Cancer Research Fund showed no association between coffee consumption and colorectal cancer risk,^[@CR10]^ but another recent review observed small reduced risks of colorectal cancer for high daily intakes of coffee (≥5 cups per day).^[@CR11]^ Other meta-analyses have not found associations between coffee consumption and gastric^[@CR12]^ or oesophageal cancer risk.^[@CR13]^ In contrast, there is evidence of an inverse association between coffee consumption and liver cancer, with two meta-analyses demonstrating that every one cup per day increase is associated with a 14--15% reduced risk of liver cancer.^[@CR14],[@CR15]^

Despite this accumulating research, few previous studies have investigated a range of digestive cancers within the same cohort. To the best of our knowledge, most studies have investigated consumption of any coffee type, caffeinated coffee or decaffeinated coffee,^[@CR15]--[@CR17]^ and only one study investigated instant coffee,^[@CR18]^ despite its biochemical compound differences, with respect to digestive cancer risk. Therefore, we aimed to investigate the association between coffee consumption and the risk of digestive cancers by type of coffee (decaffeinated, instant or ground) within a large prospective UK cohort.

Methods {#Sec2}
=======

Data source {#Sec3}
-----------

The UK Biobank contains \~500,000 volunteer participants aged 40--69 from England, Scotland and Wales recruited from 2006 to 2010.^[@CR19]^ A wide range of data were collected, including lifestyle, environment, medical history and physical measures, along with biological samples. The UK Biobank is linked to cancer-registry data from the Health and Social Care Information Centre (in England and Wales) and the National Health Service Central Register (in Scotland). Cancer registries in the United Kingdom have high completeness.^[@CR20]^ The UK Biobank has ethical approval from the North West Multi-Centre Research Ethics Committee. All participants provided written informed consent.

Study design {#Sec4}
------------

A prospective cohort study was conducted among participants in the UK Biobank. Patients diagnosed with cancers of the digestive tract were identified using cancer-registry records (based upon ICD 10 codes: oesophagus C15, including oesophageal squamous cell carcinoma and oesophageal adenocarcinoma; based upon International Classification of Diseases for Oncology codes: stomach C16; small intestine C17; colon C18; rectal and anal cancer, including rectosigmoid junction cancer C19, rectum cancer C20 and anal cancer C21; liver C22, hepatocellular carcinoma C22.0 and intrahepatic bile duct C22.1; gallbladder and extrahepatic bile duct C23--C24; pancreas C25) up to September 30, 2014. Participants with any cancer diagnosis prior to baseline or in the year after baseline were excluded (to avoid reverse causation). Consequently, cohort participants were followed from 1 year after baseline, until the date of cancer diagnosis or censoring (on the earliest of the date of death, date of other cancer diagnosis or September 30, 2014).

Exposure assessment {#Sec5}
-------------------

Coffee consumption was assessed at baseline. Participants were asked their average intake of coffee in the last year: "how many cups of coffee do you drink each day", and the most common type of coffee used (decaffeinated, instant, ground or other type).

Covariates {#Sec6}
----------

Covariates were determined from patient interview or touchscreen at baseline. These included age, sex, education (the highest qualification achieved), Townsend deprivation scores (a socio-economic measure based on area of residence)^[@CR21]^ and comorbidities (high cholesterol, diabetes, hypertension, angina, myocardial infarction, stroke, peptic ulcer disease, hepatitis, cirrhosis and gallstones). Lifestyle factors, including physical activity (metabolic equivalents (METs) score was calculated based on the number of days per week with more than 10 min of walking, moderate or vigorous physical activity),^[@CR22]^ fruit and vegetable intake (portions per day), tea intake (number of cups per day), smoking status (never smoker, previous smoker or current smoker) and alcohol consumption (never, \<1 day per week, 1--2 days per week, 3--4 days per week or \>4 days per week), were also ascertained. Body mass index (BMI) in kg/m^2^ (categorized as under- or normal weight \[\<25\], overweight \[25 to \<30\] or obese \[30 or higher\]) was calculated from height and weight measurements recorded at baseline by trained research staff. Categorical characteristics were compared by coffee consumption (yes/no) using chi-square tests.

Statistical analysis {#Sec7}
--------------------

The UK Biobank cohort was analysed using Cox regression with age as the underlying timescale (individuals were considered at risk from birth and under observation from age at baseline, left truncated) to calculate hazard ratios (HR) and 95% confidence intervals (CI) for coffee use and risk of all digestive cancers, as well as by cancer type. Dose--response analyses were conducted by increasing cups of coffee intake. In adjusted analyses, the model contained age at baseline, sex, deprivation, education, BMI, alcohol, smoking, fruit and vegetable intake, tea intake, physical activity and comorbidities at baseline (including high cholesterol, hypertension, diabetes, angina, myocardial infarction, stroke, peptic ulcer disease, hepatitis, cirrhosis and gallstones). Estimates of coffee intake by the number of cups per day and by type in association with digestive cancer were calculated. Likelihood ratio test was used to test for heterogeneity in the risk of cancer by coffee type, and in this comparison, non-users of coffee were excluded. Tests for differences in the association between coffee consumption and cancer by sex, BMI categories, alcohol consumption and smoking status, were conducted for hepatocellular carcinoma (HCC) by including interaction terms within Cox regression models.

Sensitivity analyses were performed for every site of digestive cancer and all digestive cancers by repeating the analyses starting the follow-up at 2 years after baseline (to remove cancers within 2 years, which could have influenced coffee consumption at baseline). A separate analysis was conducted for the association between coffee intake and risk of digestive cancer, in addition adjusting for a more detailed smoking status (never smoker, previous smoker \[years of cessation more than 20, 10--20 and less than 10 years\] or current smoker \[less than 10 cigarettes, 10--20 cigarettes and more than 20 cigarettes per day\]).

Figures were drawn to visualise the dose--response pattern of coffee and coffee by type in association with digestive cancer.

Results {#Sec8}
=======

A total of 471,779 participants were included in the study, following the exclusion of 30,839 participants with a previous history of cancer prior to baseline or in the year after baseline. Within the cohort, 365,157 participants (77.4%) reported drinking coffee, 104,465 participants (22.1%) reported that they did not drink coffee and in 2157 participants (0.5%) coffee consumption could not be determined. Among coffee drinkers, the type of coffee most frequently consumed was instant coffee (42.8%), followed by ground coffee (17.6%), decaffeinated coffee (14.7%) and other types reported by 1.4%.

Table [1](#Tab1){ref-type="table"} shows the baseline characteristics of participants by coffee consumption. People who drank coffee, compared with those who did not, were more likely to be older, male, from less-deprived areas and have higher education levels. They were also more likely to be previous or current smokers, consume higher levels of alcohol, have high cholesterol and were less likely to have diabetes, cirrhosis, gallstones, and peptic ulcers compared with non-coffee drinkers.Table 1Baseline characteristics by coffee consumption within the UK BiobankCharacteristicsCoffee use*p*-valueNoYes*n*104,465 (22.1%)365,157 (77.4%)*Age at baseline (years)*  0--4929,969 (28.7%)84,182 (23.1%)  50--5936,583 (35.0%)121,413 (33.2%)  60--6937,513 (35.9%)157,846 (43.2%)\<0.001  70+400 (0.4%)1716 (0.5%)Male44,004 (42.1%)172,206 (47.2%)\<0.001*Deprivation*  1 (least deprived)17,825 (17.1%)76,482 (20.9%)  218,848 (18.1%)75,006 (20.5%)  319,880 (19.0%)73,840 (20.2%)\<0.001  421,945 (21.0%)72,053 (19.7%)  5 (most deprived)25,828 (24.7%)67,325 (18.4%)  Missing139 (0.1%)451 (0.1%)*Education*  College or university degree27,872 (26.7%)124,155 (34.0%)  A level/AS level or equivalent10,880 (10.4%)41,252 (11.3%)  O level/GCSEs or equivalent22,221 (21.3%)76,381 (20.9%)  CSEs or equivalent6963 (6.7%)18,690 (5.1%)\<0.001  NVQ or HND or HNC equivalent7348 (7.0%)23,358 (6.4%)  Other professional qualifications5113 (4.9%)18,800 (5.1%)  None of the above21,679 (20.7%)56,480 (15.5%)  Missing2389 (2.3%)6041 (1.7%)*BMI*  Normal/underweight34,646 (33.2%)119,867 (32.8%)  Overweight42,406 (40.6%)156,214 (42.8%)\<0.001  Obese26,636 (25.5%)87,349 (23.9%)  Missing777 (0.7%)1727 (0.5%)*Smoking status*  Never61,572 (58.9%)195,888 (53.6%)  Previous32,229 (30.8%)128,414 (35.2%)\<0.001  Current10,235 (9.8%)39,574 (10.8%)  Missing429 (0.4%)1281 (0.4%)*Alcohol consumption*  Never15,214 (14.6%)22,324 (6.1%)  \<1 day per week29,697 (28.4%)76,527 (20.9%)  1--2 days per week25,970 (24.9%)95,315 (26.1%)\<0.001  3--4 days per week18,424 (17.6%)90,390 (24.8%)  \>4 days per week15,045 (14.4%)80,321 (22.0%)  Missing115 (0.1%)280 (0.1%)*Fruit and vegetable intake*  \<2.5 portions per day22,939 (21.9%)68,417 (18.7%)  2.5--5 portions per day39,898 (38.2%)149,040 (40.8%)\<0.001  \>=5 portions per day38,251 (36.6%)138,186 (37.8%)  Missing3377 (3.3%)9514 (2.6%)*Physical activity*  Low14,539 (13.9%)47,718 (13.1%)  Moderate31,313 (30.0%)119,318 (32.7%)  High32,617 (31.2%)116,169 (31.8%)\<0.001  Missing25,996 (24.9%)81,952 (22.4%)*Comorbidities*  High cholesterol12,172 (11.7%)44,859 (12.3%)\<0.001  Diabetes5763 (5.5%)17,856 (4.9%)\<0.001  Hepatitis520 (0.5%)1856 (0.5%)0.45  Cirrhosis129 (0.12%)348 (0.10%)0.041  Gallstones1775 (1.7%)5700 (1.5%)0.002  Peptic ulcers1599 (1.5%)4090 (1.1%)\<0.001*BMI* body mass index, *CSE* Certificate of Secondary Education, *GCSE* General Certificate of Secondary Education, *HNC* Higher National Certificate, *HND* Higher National Diploma, *NVQ* National Vocational Qualification

Over 7.5 years of follow-up, 3567 digestive cancer cases were detected. The associations between any type of coffee consumption and risk of specific digestive cancers are presented in Table [2](#Tab2){ref-type="table"}. In adjusted analysis, any coffee consumption was only associated with HCC (adjusted HR: 0.50, 95% CI: 0.29--0.87) and was not significantly associated with other cancers. The results were largely similar in dose--response analyses of increasing the number of coffee cups consumed per day compared with non-coffee drinkers. The association of oesophageal squamous cell carcinoma and coffee intake followed a dose-- response relationship (adjusted HR per cup increase 1.08, 95% CI: 1.02--1.16) and an increased risk was observed in those drinking more than five cups (adjusted HR: 2.88, 95% CI: 1.20--6.92). There was some evidence of reductions in HCC risk with increasing the categories of coffee cups consumed (e.g., adjusted HR for ≥5 cups: 0.44, 95% CI: 0.17--1.12 and p for trend = 0.07), as well as per cup increase (adjusted HR: 0.87, 95% CI: 0.76--1.01).Table 2The association between coffee intake by the number of cups per day and digestive cancer within the UK BiobankCoffee intake (cups/day)HR per cup increasep-trend0Any\>0--23--4≥5*n*104,465365,157215,73997,02252,396*Oesophageal cancer* Cases742791467261 Unadjusted HR1.000.97 (0.75, 1.25)0.84 (0.63, 1.11)0.93 (0.67, 1.29)1.60 (1.14, 2.24)1.07 (1.03, 1.10)\<0.001 Adjusted HR1.001.15 (0.83, 1.61)1.11 (0.77, 1.58)1.08 (0.71, 1.65)1.47 (0.94, 2.30)1.03 (0.98, 1.07)0.28*Oesophageal squamous cell carcinoma* Cases1561281518 Unadjusted HR1.001.05 (0.60, 1.86)0.80 (0.42, 1.51)0.97 (0.47, 1.99)2.34 (1.18, 4.64)1.09 (1.03, 1.15)0.001 Adjusted HR1.001.26 (0.59, 2.67)0.94 (0.41, 2.14)1.10 (0.42, 2.87)2.88 (1.20, 6.92)1.08 (1.02, 1.16)0.01*Oesophageal adenocarcinoma* Cases552041105242 Unadjusted HR1.000.94 (0.70, 1.27)0.84 (0.61, 1.17)0.90 (0.61, 1.32)1.47 (0.98, 2.20)1.06 (1.01, 1.11)0.008 Adjusted HR1.001.21 (0.81, 1.80)1.25 (0.83, 1.89)1.07 (0.65, 1.76)1.25 (0.72, 2.15)1.00 (0.93, 1.07)0.96*Gastric cancer* Cases65184995530 Unadjusted HR1.000.72 (0.55, 0.96)0.65 (0.47, 0.88)0.81 (0.56, 1.16)0.90 (0.58, 1.39)1.00 (0.95, 1.07)0.79 Adjusted HR1.000.98 (0.68, 1.41)0.88 (0.59, 1.30)1.14 (0.73, 1.79)1.18 (0.70, 1.98)1.03 (0.97, 1.09)0.30*Small intestinal cancer* Cases1463312012 Unadjusted HR1.001.18 (0.66, 2.11)0.97 (0.51, 1.82)1.40 (0.71, 2.78)1.68 (0.78, 3.64)1.05 (0.96, 1.14)0.27 Adjusted HR1.001.39 (0.60, 2.87)1.12 (0.49, 2.58)1.67 (0.67, 4.18)1.65 (0.56, 4.78)1.02 (0.90, 1.17)0.65*Colon cancer* Cases3201141666340135 Unadjusted HR1.000.93 (0.82, 1.05)0.90 (0.79, 1.03)1.04 (0.89, 1.21)0.82 (0.67, 1.00)0.98 (0.95, 1.00)0.16 Adjusted HR1.000.91 (0.78, 1.05)0.89 (0.76, 1.05)0.97 (0.80, 1.18)0.87 (0.68, 1.11)0.97 (0.93, 1.01)0.15*Rectal and anal cancer* Cases17661036115594 Unadjusted HR1.000.91 (0.77, 1.08)0.90 (0.76, 1.08)0.87 (0.70, 1.08)1.04 (0.81, 1.33)1.01 (0.98, 1.04)0.37 Adjusted HR1.000.88 (0.72, 1.08)0.90 (0.72, 1.11)0.81 (0.62, 1.06)0.95 (0.70, 1.30)1.00 (0.96, 1.04)0.90*Liver cancer* Cases48134823220 Unadjusted HR1.000.72 (0.52, 1.00)0.74 (0.52, 1.05)0.65 (0.41, 1.01)0.81 (0.48, 1.37)0.96 (0.89, 1.04)0.34 Adjusted HR1.000.87 (0.58, 1.30)0.88 (0.57, 1.36)0.87 (0.51, 1.48)0.83 (0.45, 1.55)0.97 (0.89, 1.05)0.44*Hepatocellular carcinoma* Cases266239149 Unadjusted HR1.000.61 (0.39, 0.97)0.64 (0.39, 1.05)0.52 (0.27, 1.00)0.68 (0.32, 1.45)0.93 (0.82, 1.04)0.22 Adjusted HR1.000.50 (0.29, 0.87)0.55 (0.30, 1.00)0.44 (0.20, 0.96)0.44(0.17, 1.12)0.87 (0.76, 1.01)0.07*Intrahepatic bile duct carcinoma* Cases165636146 Unadjusted HR1.000.90 (0.52, 1.57)0.97 (0.53, 1.74)0.84 (0.41, 1.73)0.72 (0.28, 1.85)0.95 (0.84, 1.07)0.43 Adjusted HR1.001.49 (0.71, 3.11)1.47 (0.68, 3.18)1.80 (0.74, 4.34)1.06 (0.32, 3.48)1.00 (0.88, 1.14)0.90*Gallbladder and extrahepatic bile duct carcinoma* Cases1481472014 Unadjusted HR1.001.48 (0.84, 2.61)1.43 (0.78, 2.59)1.37 (0.69, 2.71)1.93 (0.92, 4.06)1.05 (0.96, 1.13)0.23 Adjusted HR1.001.63 (0.81, 3.27)1.52 (0.74, 3.15)1.56 (0.67, 3.64)2.40 (0.98, 5.90)1.06 (0.97, 1.15)0.15*Pancreatic cancer* Cases813031718349 Unadjusted HR1.000.95 (0.75, 1.22)0.89 (0.68, 1.16)0.98 (0.72, 1.33)1.17 (0.82, 1.67)1.03 (0.98, 1.07)0.17 Adjusted HR1.000.89 (0.66, 1.20)0.86 (0.63, 1.18)0.88 (0.60, 1.28)1.08 (0.71, 1.65)1.02 (0.97, 1.06)0.44*All digestive cancers* Cases78427671,581773413 Unadjusted HR1.000.91 (0.84, 0.99)0.87 (0.80, 0.95)0.96 (0.87, 1.06)1.02 (0.91, 1.15)1.01 (0.99, 1.02)0.17 Adjusted HR1.000.95 (0.86, 1.05)0.92 (0.83, 1.02)0.98 (0.87, 1.11)1.05 (0.90, 1.21)1.00 (0.98, 1.02)0.53The model contains age at baseline, sex, deprivation, education, BMI, alcohol, smoking, fruit and vegetable intake, tea intake, physical activity and comorbidities at baseline (including high cholesterol, hypertension, diabetes, angina, myocardial infarction, stroke, peptic ulcer disease, hepatitis, cirrhosis and gallstones)

Associations between coffee consumption by type and risk of specific digestive cancers are presented in Table [3](#Tab3){ref-type="table"}. The reduction of HCC risk ranged from 41 to 53% for different types of coffee, which was most apparent for instant coffee (adjusted HR: 0.51, 95% CI: 0.28--0.93); however, there was no evidence of the difference in the risk of HCC by type of coffee (*p* = 0.53). The risk of pancreatic cancer was reduced by 34% in users of decaffeinated coffee compared with non-coffee drinkers, but this did not reach statistical significance (adjusted HR: 0.66, 95% CI: 0.43--1.01). No significant associations were observed for any coffee type and risk of stomach, oesophagus, small intestine, colon, rectal and anal cancer or intrahepatic bile duct carcinoma (Table [3](#Tab3){ref-type="table"}). The risk of gallbladder and extrahepatic bile duct carcinoma was consistently increased with consumption of any type of coffee, but the only significant increase in risk was observed for decaffeinated coffee (HR 2.44, 95% CI: 1.10--5.38).Table 3The association between coffee type and digestive cancer within the UK BiobankMost common type of coffee usedNon-useDecaffeinatedInstantGroundOther typesHeterogeneity p^a^*n*104,46569,363201,91282,8656674*Oesophageal cancer* Cases7453166467 Unadjusted HR1.000.91 (0.64, 1.30)1.03 (0.78, 1.36)0.76 (0.52, 1.09)1.43 (0.66, 3.11)0.18 Adjusted HR1.001.27 (0.82, 1.98)1.12 (0.78, 1.59)1.08 (0.78, 1.59)1.58 (0.56, 4.41)0.63*Oesophageal squamous cell carcinoma* Cases1514368\<5 Unadjusted HR1.001.21 (0.58, 2.52)1.12 (0.61, 2.05)0.65 (0.27, 1.54)2.04 (0.46, 8.92)0.54 Adjusted HR1.001.27 (0.46, 3.51)1.16 (0.52, 2.58)1.03 (0.38, 2.83)4.17 (0.89,19.46)0.87*Oesophageal adenocarcinoma* Cases5536122356 Unadjusted HR1.000.83 (0.54, 1.26)1.01 (0.73, 1.39)0.77 (0.50, 1.18)1.64 (0.71, 3.83)0.60 Adjusted HR1.001.33 (0.79, 2.24)1.18 (0.78, 1.80)1.17 (0.69, 1.97)1.65 (0.50, 5.41)0.63*Gastric cancer* Cases652911731\<5 Unadjusted HR1.000.57 (0.37, 0.88)0.83 (0.61, 1.12)0.59 (0.38, 0.90)0.93 (0.34, 2.56)0.13 Adjusted HR1.000.88 (0.52, 1.48)1.04 (0.70, 1.52)0.87 (0.52, 1.45)0.90 (0.22, 3.76)0.69*Small intestinal cancer* Cases14113512\<5 Unadjusted HR1.001.04 (0.47, 2.30)1.18 (0.63, 2.20)1.06 (0.49, 2.29)2.20 (0.50, 9.70)0.82 Adjusted HR1.001.70 (0.65, 4.41)1.07 (0.46, 2.51)1.16 (0.42, 3.15)4.39 (0.93, 20.8)0.34*Colon cancer* Cases32022065022322 Unadjusted HR1.000.90 (0.76, 1.07)0.95 (0.83, 1.09)0.86 (0.72, 1.02)1.05 (0.68, 1.62)0.51 Adjusted HR1.000.95 (0.78, 1.17)0.91 (0.77, 1.07)0.84 (0.68, 1.04)1.21 (0.73, 2.02)0.50*Rectal and anal cancer* Cases1761033711198 Unadjusted HR1.000.77 (0.61, 0.99)0.99 (0.83, 1.19)0.83 (0.66, 1.05)0.69 (0.34, 1.42)0.06 Adjusted HR1.000.83 (0.62, 1.11)0.95 (0.76, 1.18)0.80 (0.60, 1.05)0.56 (0.20, 1.53)0.39*Liver cancer* Cases48238026\<5 Unadjusted HR1.000.62 (0.37, 1.02)0.77 (0.54, 1.11)0.67 (0.41, 1.07)0.95 (0.29, 3.06)0.72 Adjusted HR1.000.82 (0.45, 1.49)0.91 (0.59, 1.41)0.84 (0.47, 1.50)0.58 (0.07, 4.24)0.92*Hepatocellular carcinoma* Cases26113711\<5 Unadjusted HR1.000.54 (0.27, 1.10)0.66 (0.40, 1.09)0.52 (0.25, 1.05)1.17 (0.28, 4.95)0.71 Adjusted HR1.000.59 (0.25, 1.37)0.51 (0.28, 0.93)0.47 (0.20, 1.08)Too small0.53*Intrahepatic bile duct carcinoma* Cases1693312\<5 Unadjusted HR1.000.72 (0.32, 1.64)0.95 (0.52, 1.73)0.92 (0.43, 1.94)0.95 (0.12, 7.17)0.91 Adjusted HR1.000.97 (0.38, 2.43)1.27 (0.63, 2.55)1.46 (0.63, 3.35)1.48 (0.19,11.54)0.91*Gallbladder and extrahepatic bile duct carcinoma* Cases14253418\<5 Unadjusted HR1.002.28 (1.18, 4.39)1.11 (0.60, 2.08)1.57 (0.78, 3.16)2.17 (0.78, 3.16)0.06 Adjusted HR1.002.44 (1.10, 5.38)1.33 (0.63, 2.82)1.84 (0.77, 4.44)Too small0.11*Pancreatic cancer* Cases814617869\<5 Unadjusted HR1.000.72 (0.50, 1.03)1.00 (0.77, 1.31)1.04 (0.75, 1.43)0.93 (0.37, 2.30)0.17 Adjusted HR1.000.66 (0.43, 1.03)0.95 (0.69, 1.29)0.99 (0.68, 1.45)0.81 (0.25, 2.60)0.31*All digestive cancers* Cases784507161453653 Unadjusted HR1.000.84 (0.75, 0.94)0.96 (0.88, 1.04)0.84 (0.75, 0.93)1.03 (0.78, 1.36)0.007 Adjusted HR1.000.95 (0.83, 1.09)0.97 (0.87, 1.07)0.89 (0.78, 1.02)1.03 (0.72, 1.47)0.61The model contains age at baseline, sex, deprivation, education, BMI, alcohol, smoking, fruit and vegetable intake, tea intake, physical activity and comorbidities at baseline (including high cholesterol, hypertension, diabetes, angina, myocardial infarction, stroke, peptic ulcer disease, hepatitis, cirrhosis and gallstones)^a^P-value for likelihood ratio test comparing cancer risk by coffee type (decaffeinated, instant, ground and other types)

After excluding the 2 years following baseline, the association between increasing the number of coffee cups consumed per day and digestive cancer risk showed similar results to the main analysis (Supplementary Table [1](#MOESM1){ref-type="media"}). In similar analysis by coffee type, associations were little altered for any digestive cancer site, except for gallbladder and extrahepatic bile duct carcinoma, which attenuated and became non-significant (Supplementary Table [2](#MOESM1){ref-type="media"}).

An additional analysis was conducted for the association between coffee intake and risk of digestive cancer, in addition adjusting for a more detailed smoking status. The association was observed to be similar to the main analysis (Supplementary Table [3](#MOESM1){ref-type="media"}). Analysis for HCC stratifying by sex, BMI, alcohol consumption and smoking status found similar association to the main analysis (Supplementary Table [4](#MOESM1){ref-type="media"}). No interaction was found.

Supplementary Figures [1](#MOESM1){ref-type="media"} and [2](#MOESM1){ref-type="media"} were drawn to visualise the dose--response pattern of coffee and coffee by type in association with digestive cancer.

Discussion {#Sec9}
==========

In a large prospective study, we found that a reduced risk of HCC with coffee consumption, which was consistent with dose--response analysis and by coffee type, was apparent for instant coffee.

Our study is consistent with the inverse association between coffee consumption and HCC risk that has been judged as "convincing" evidence in the 2018 World Cancer Research Fund report,^[@CR15]^ confirming previous individual studies^[@CR16],[@CR17],[@CR23]^ and meta-analyses.^[@CR24],[@CR25]^ Whilst we did not show marked differences in the inverse association between HCC and coffee consumption by type of coffee, an inverse association was apparent for instant coffee. Some previous studies have investigated caffeinated and decaffeinated coffee,^[@CR16],[@CR17],[@CR23]^ but no previous studies, to date, have explored the association of instant coffee consumption and HCC.

The underlying biological mechanisms for a reduced risk of HCC with coffee consumption, especially with instant coffee, are not well known, but some mechanisms have been proposed. Coffee has high levels of antioxidants,^[@CR26]^ including phenolic acids, diterpenes like cafestol and kahweol and tocopherols.^[@CR27]^ Compounds, such as phenolic acids^[@CR28],[@CR29]^ and caffeine,^[@CR30]^ have also been shown to have chemopreventive properties, including in liver carcinogenesis.^[@CR31]^ These compounds have been shown to inhibit the proliferation of HCC cell lines in vitro and suppress the progression of HCC in vivo,^[@CR32]^ while chlorogenic acid has been shown to prevent oxidative damage in hepatocytes.^[@CR33]^ Instant coffee, in comparison with ground and decaffeinated coffee, has been demonstrated to have higher levels of those biochemical compounds,^[@CR3],[@CR4]^ which therefore could partly explain the more marked reduced risk of HCC in our study. The underlying potential anticancer mechanism of instant coffee has also been observed in previous experimental studies. An animal study^[@CR5]^ showed that mice receiving instant coffee had a reduction in the size and the number of hepatocellular neoplastic lesions, compared with mice receiving ground coffee. Instant coffee administration in rats also resulted in a significantly higher expression of bax protein,^[@CR5]^ which monitors cell apoptosis and is a known tumour suppressor.^[@CR34],[@CR35]^ Another study in rats demonstrated that instant coffee powder inhibited hepatoma cell proliferation, reduced metastasis and positively altered lipoprotein profiles.^[@CR36]^ Therefore, it is plausible that instant coffee may have stronger anticancer effects in comparison with other coffee types.

For other individual types of digestive cancer, we did not find any consistent association with coffee consumption. Our findings of no association between coffee and colorectal cancer confirm previous findings,^[@CR10],[@CR37]^ although they contrast with suggestions that high levels of coffee drinking reduced the risk of colon cancer.^[@CR11]^ For small intestine and oesophageal cancer, our findings are similar to previous meta-analyses of no association with coffee consumption.^[@CR13],[@CR38]^ However, our study found an increased risk of oesophageal squamous cell carcinoma with high intake of coffee, which was not consistent with the literature. A study in a Norwegian population found no association between high coffee intake and the risk of oesophageal squamous cell carcinoma.^[@CR31]^ Similarly, another study found that higher intake of isoflavones, for which coffee was the major source, was not associated with the risk of oesophageal squamous cell carcinoma.^[@CR39]^

For gastric cancer, the results are inconclusive. Our findings of no association between coffee and the risk of gastric cancer are in line with a recent meta-analysis;^[@CR12]^ however, contrasting two previous meta-analyses showed a decrease^[@CR40]^ and an increase in the risk of gastric cancer with coffee use.^[@CR41]^ In one meta-analysis, no association was observed following restriction to only cohort studies,^[@CR40]^ while in the other meta-analysis, the positive association between coffee consumption and gastric cancer risk attenuated and became non-significant after adjusting for risk factors, such as smoking, alcohol intake and BMI.^[@CR41]^

Our study is similar to a more recent meta-analysis of four large cohort studies of female non-smokers, which demonstrated no association between coffee intake and pancreatic cancer.^[@CR42]^ Our study found no association between increasing the number of coffee cups consumed and pancreatic cancer risk, but there was suggestive evidence of an inverse association between decaffeinated coffee consumption and pancreatic cancer risk, which is in contrast to a previous US study, showing no association for decaffeinated coffee.^[@CR43]^ The difference in the results might be explained by other underlying differences in population behaviours relevant for pancreatic cancer aetiology, or differences in coffee consumption patterns, but is difficult to fully understand. Further investigations are warranted to explore the association between decaffeinated coffee and pancreatic cancer.

Our findings of an increased risk of gallbladder cancer with decaffeinated coffee consumption are not consistent with a previous meta-analysis of any coffee intake and biliary tract cancer risk, although the previous study did not specifically investigate decaffeinated coffee.^[@CR14]^ However, our result could be owing to chance, since there was no clear dose--response relationship, and the positive finding attenuated and became non-significant in sensitivity analysis.

Acrylamide is a chemical produced by the coffee-roasting process, particularly in the production of instant coffee,^[@CR6]^ classified by IARC in group 2A as a probable human carcinogen.^[@CR7]^ Acrylamide has been shown to have a carcinogenic effect in animal studies;^[@CR44]^ however, in epidemiological studies of humans, the association with gastrointestinal cancer is controversial. For instance, a prospective study investigating daily acrylamide intake did not find an association with oesophageal, gastric, colorectal and pancreatic cancer.^[@CR45]^ In contrast, another study from the European Prospective Investigation into Cancer and Nutrition cohort found a significantly increased risk of oesophageal cancer with acrylamide intake.^[@CR46]^ Our study generally provides reassurance that coffee consumption, known to be high in acrylamide, does not appear to be associated with increased gastrointestinal cancer risk.

The main strength of our study is that within the UK Biobank, information on the type of coffee most commonly consumed was available, allowing for investigation of instant or ground or decaffeinated coffee and digestive cancer risk. Second, the UK Biobank contains over 500,000 participants who were prospectively followed for up to 7.5 years, allowing sufficient statistical power to detect even relatively weak associations. We were also able to investigate the impact of coffee consumption across a number of different digestive cancer sites, therefore minimizing potential measurement error. Finally, we were able to control for various important confounders, which are associated with coffee consumption and digestive cancer risk, such as BMI, alcohol and smoking habit, physical activity, fruit and vegetable intake, tea intake and comorbidities.

However, a number of weaknesses existed in our study. First, coffee consumption could have changed over time, so misclassification of coffee consumption is possible. However, other cohorts have shown coffee consumption to remain relatively stable over time in adult populations.^[@CR47]^ Second, there were small numbers of cases of certain cancers in our study (e.g., small intestine cancer, intrahepatic bile duct carcinoma, gallbladder and extrahepatic bile duct carcinoma), and therefore for these cancers, we would have limited power to detect associations with coffee consumption. Third, we did not have information on H. pylori infection; therefore, we were unable to adjust for this potential confounder in analyses of oesophageal or gastric cancer. Fourth, we did not investigate the impact of milk, non-dairy creamer and sweeteners on the association between coffee and digestive cancer risk. Milk and non-dairy creamer have been found to alter the biochemical activities of coffee by interacting with coffee components like polyphenol;^[@CR48]^ however, the extent of its impact on the association of coffee and cancer risk has not yet been substantiated. Measurement error of coffee intake might have affected our ability to identify true associations with cancers. In particular, it is possible that measurement error, which is likely to dilute any real associations, both reduced the magnitude of the association between coffee intake and HCC and dragged weaker associations between coffee intake and other GI cancers to the null. Finally, as a large number of tests were conducted, increasing the likelihood of Type 1 error, significant results should be interpreted cautiously. Further studies should investigate the underlying mechanisms of the inverse association between coffee and HCC. Additional large epidemiological studies are required to confirm the role of instant coffee among other types, as well as the impact of milk, non-dairy creamer and sweeteners in the association with digestive cancers.

In conclusion, our findings suggest an inverse association between coffee consumption and hepatocellular carcinoma, which was similar by coffee types. However, whether the observed association reflects a causal relationship, and if so, the underlying mechanisms are responsible, is worthy of further investigation.
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